• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    11/14/24 7:00:55 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $REPL alert in real time by email
    SC 13G/A 1 d910286dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    Replimune Group, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001

    (Title of Class of Securities)

    76029N106

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 76029N106    13G    Page 2 of 6 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Forbion Capital Fund III Coöperatief U.A.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     SOLE VOTING POWER

     

     0

       6.  

     SHARED VOTING POWER

     

     5,115,121*

       7.  

     SOLE DISPOSITIVE POWER

     

     0

       8.  

     SHARED DISPOSITIVE POWER

     

     5,115,121*

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,115,121*

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     7.5% (1)

    12.  

     TYPE OF REPORTING PERSON

     

     OO

     

    *

    Includes 248,672 shares of common stock issuable upon exercise of warrants to purchase shares of common stock.

    1

    This percentage is calculated based upon (i) 68,321,396 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s quarterly report in Form 10-Q, filed with the Securities and Exchange Commission on August 8, 2024, plus (ii) 248,672 shares of common stock underlying warrants held by the Reporting Persons.


    CUSIP No. 76029N106    13G    Page 3 of 6 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Forbion III Management B.V.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.   

     SOLE VOTING POWER

     

     0

       6.  

     SHARED VOTING POWER

     

     5,115,121*

       7.  

     SOLE DISPOSITIVE POWER

     

     0

       8.  

     SHARED DISPOSITIVE POWER

     

     5,115,121*

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,115,121

    10.  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     7.5% (2)

    12.  

     TYPE OF REPORTING PERSON

     

     OO

     

    *

    Includes 248,672 shares of common stock issuable upon exercise of warrants to purchase shares of common stock.

    2

    This percentage is calculated based upon (i) 68,321,396 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s quarterly report in Form 10-Q, filed with the Securities and Exchange Commission on August 8, 2024, plus (ii) 248,672 shares of common stock underlying warrants held by the Reporting Persons.


    Item 1(a).

    Name of Issuer:

    Replimune Group, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    500 Unicorn Park Drive, Suite 303, Woburn, MA 01801

     

    Item 2(a).

    Name of Person Filing:

    This Statement is being filed by Forbion Capital Fund III Coöperatief U.A. (“Forbion III COOP”), and Forbion III Management B.V. (“Forbion III”), the director of Forbion III COOP. Forbion III COOP and Forbion III are sometimes referred to collectively herein as the “Reporting Persons”.

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business and principal office of each of the Reporting Persons is c/o Forbion Capital Partners, Gooimeer 2-35, 1411 DC Naarden, The Netherlands.

     

    Item 2(c).

    Citizenship:

    Forbion Capital Fund III Coöperatief U.A. – The Netherlands

    Forbion III Management B.V. – The Netherlands

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.001 per share

     

    Item 2(e).

    CUSIP Number:

    76029N106

     

    Item 3.

    Not applicable.

     

    Item 4.

    Ownership.

    Forbion III COOP is the beneficial owner of 5,115,121 shares of Common Stock, consisting of (i) 4,866,449 shares of common stock and (ii) 248,672 shares of common stock issuable upon exercise of warrants beneficially owned by the Reporting Persons. Forbion III, the director of Forbion III COOP, has voting and investment power over the shares held by Forbion III COOP.

     

      (a)

    Amount beneficially owned: 5,115,121

     

      (b)

    Percent of class: 7.5%

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote: 0

     

      (ii)

    Shared power to vote or to direct the vote: 5,115,121

     

      (iii)

    Sole power to dispose or to direct the disposition of: 0

     

      (iv)

    Shared power to dispose or to direct the disposition of: 5,115,121

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.


    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    The Reporting Persons are making this single, joint filing because they may be deemed to constitute a “group” within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Reporting Persons disclaim membership in a group and this report shall not be deemed an admission by any of the Reporting Persons that they are or may be members of a “group” for purposes of Rule 13d-5 or for any other purpose.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    Not applicable.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: November 14, 2024

     

    FORBION CAPITAL FUND III COÖPERATIEF U.A.
    By: Forbion III Management B.V.
    Its: Director

    /s/ G.J. Mulder

            

    /s/ V. van Houten

    Name: G.J. Mulder       V. van Houten
    Title: Directors      
    FORBION III MANAGEMENT B.V.

    /s/ G.J. Mulder

         

    /s/ V. van Houten

    Name: G.J. Mulder       V. van Houten
    Title: Directors      
    Get the next $REPL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REPL

    DatePrice TargetRatingAnalyst
    6/20/2025Overweight
    Cantor Fitzgerald
    8/28/2024$17.00Buy
    ROTH MKM
    4/17/2023$44.00Overweight
    Piper Sandler
    11/19/2021$52.00Overweight
    Piper Sandler
    10/15/2021$60.00Buy
    BTIG Research
    8/23/2021$55.00 → $49.00Outperform
    SVB Leerink
    8/9/2021$56.00 → $55.00Outperform
    SVB Leerink
    More analyst ratings

    $REPL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 10 employees as a material inducement to commencing their employment with the Company under the Company's 2025 Inducement Grant Incentive Compensation Plan (the "Inducement Plan"). The inducement awards consist of non-qualified stock options to purchase an aggregate of 36,485 shares of the Company's common stock and restricted stock units representing an aggregate of 41,080 s

      6/6/25 4:01:00 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

      - RP1 plus nivolumab generated robust responses in both injected and non-injected lesions - - Deep/visceral injections, including into the liver and lung, resulted in numerically higher rates of response compared to superficial injections only and were generally well tolerated - WOBURN, Mass., June 01, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented two posters highlighting data updates for RP1 (vusolimogene oderparepvec) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago. "The new analyses we pres

      6/1/25 10:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune to Present at the 2025 Jefferies Global Healthcare Conference

      WOBURN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 4:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune's website at replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering th

      5/29/25 8:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care